Atlas Trials

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

Clinical trial NCT02402712 · COMPLETED

Trial details

NCT number
NCT02402712
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2015-05-06
Primary completion
2019-02-22
Enrollment
418

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.